1. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Issue 3 (14th March 2019) Authors: Kloppenburg, Margreet; Peterfy, Charles; Haugen, Ida K; Kroon, Féline; Chen, Su; Wang, Li; Liu, Wei; Levy, Gwen; Fleischmann, Roy M; Berenbaum, Francis; van der Heijde, Désirée; Bansal, Prashant; Wittoek, Ruth; Feng, Sheng; Fang, Yuni; Saltarelli, Mary; Medema, Jeroen K; Levesque, Marc C Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 3(2019) Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Issue 3 (14th December 2018) Authors: Kloppenburg, Margreet; Peterfy, Charles; Haugen, Ida K; Kroon, Féline; Chen, Su; Wang, Li; Liu, Wei; Levy, Gwen; Fleischmann, Roy M; Berenbaum, Francis; van der Heijde, Désirée; Bansal, Prashant; Wittoek, Ruth; Feng, Sheng; Fang, Yuni; Saltarelli, Mary; Medema, Jeroen K; Levesque, Marc C Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 3(2019) Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗